Anti-cholinergic drugs are one of the commonly used drugs in Medicine. They are used for variety of conditions like Depression, Parkinson's disease, Epilepsy, Gastrointestinal diseases and number of urologic conditions. Anti-cholinergic drugs block the neurotransmitter acetylcholine in the central or peripheral nervous system, and have diverse actions. Examples of commonly used drugs include Diphenhydramine, Trihexyphenidyl, Benztropine, Biperiden, Clomipramine, Chlorpromazine, Clozapine Fluphenazine, Loxapine, Olanzapine, Perphenazine, Pimozide, Quetiapine, Thioridazine, Thiothixene, Trifluoperazine, Dicyclomine, Hyoscyamine, Flavoxate, Glycopyrrolate, Oxybutynin, Propantheline, Scopolamine, Tiotropium, Tolterodine etc.,
Dementia is the term denoted for a decline in mental ability severe enough to interfere with daily life. Common forms of dementia include Alzheimer's disease and Vascular dementia (which occur post stroke). Other causes for Dementia include Thyroid diseases and vitamin deficiencies. Dementia is one of the leading causes of disability and death, and its prevention is a global public health priority.
Several Research studies have studied the association between Anti-cholinergic drugs and cognitive dysfunction. Over the past decade, prolonged exposure to anti-cholinergic drugs has been linked to long term cognitive decline or dementia incidence among community living cohorts and nursing home residents. Large group of elderly patients have been studied at United Kingdom with a varying history of Anti-cholinergic drug use. Study concluded that Mechanistic evidence for a link between anticholinergic drugs and dementia incidence is limited, but neuropathological studies in humans and mice do support a role of anticholinergics affecting neurodegenerative pathology. Many people use anticholinergic drugs at some point in their lives, and many are prescribed to manage chronic conditions leading to potentially long exposures. There are strong associations between levels of anticholinergic antidepressants, antiparkinsons, and urologicals and the risk of a diagnosis of dementia up to 20 years after exposure.
Reference:
1. Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, Myint PK, Grossi CM, Mattishent K, Bennett K, Campbell NL, Boustani M, Robinson L, Brayne C, Matthews FE1, Savva GM. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018 Apr 25;361:k1315.
2.Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, Medical Research Council Cognitive Function and Ageing Study. Age, neuropathology, and dementia. N Engl J Med2009;360:2302-9.
3.Matthews FE, Arthur A, Barnes LE, et al., Medical Research Council Cognitive Function and Ageing Collaboration. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet2013;382:1405-12.
4.Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc2011;59:1477-83.
5.Chatterjee S, Bali V, Carnahan RM, Johnson ML, Chen H, Aparasu RR. Anticholinergic Medication Use and Risk of Dementia Among Elderly Nursing Home Residents with Depression. Am J Geriatr Psychiatry2016;24:485-95.
6.Boustani M, Campbell N, Munger S, et al. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health2008;4:311-20.
Mr. Vishwas H N
Lecturer
Department of Pharmacy Practice,
JSS College of Pharmacy,
Ooty, Tamilnadu